Nothing has been decided yet, and we may still be far from seeing the new company emerging; both parties have been active in the digital health space.
Under the deal, Novartis will use Qualcomm Life's connectivity solutions to power its next-gen connected Breezhaler, the inhaler for its COPD portfolio.
The goal of the competition is to create a mobile device much like the medical Tricorder of Star Trek fame, moving it from science fiction to science reality.
The chip maker's VC arm, Qualcomm Ventures, will be working with Novartis' health experts to target early stage companies and support select tech innovations.
The company applies machine-learning analytic tools to transform structured and unstructured data, along with external data sources, into actionable insights.
CCmHI will work on developing mHealth solutions, implementing clinical evaluations, and contributing to implementation of affordable mHealth tools.